Advertisement

European Journal of Epidemiology

, Volume 28, Issue 3, pp 205–221 | Cite as

Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants

  • Setor Kwadzo KunutsorEmail author
  • Tanefa Antoinette Apekey
  • Marinka Steur
META-ANALYSIS

Abstract

The evidence on the association between baseline vitamin D status and risk of incident hypertension in general populations is limited and has not been reliably quantified. We conducted a systematic review and meta-analysis of published prospective studies evaluating the associations of baseline vitamin D status (circulating 25-hydroxyvitamin D [25(OH)D] levels and dietary vitamin D intake) with risk of hypertension. Eligible studies were identified in a literature search of MEDLINE, EMBASE, and Web of Science up to November 2012. Pooled relative risks (RRs) with 95 % confidence intervals were calculated using random effects models. Generalized least-squares trend estimation was used to assess dose–response relationships. Of the 2,432 articles reviewed for eligibility, eight unique prospective cohorts with aggregate data on 283,537 non-overlapping participants and 55,816 incident hypertension cases were included. The RRs (95 % CIs) for hypertension in a comparison of extreme thirds of baseline levels of vitamin D were 0.70 (0.58, 0.86) for seven studies that measured blood 25(OH) D levels and 1.00 (0.95, 1.05) for four studies that assessed dietary vitamin D intake. The pooled RR of incident hypertension per 10 ng/mL increment in baseline 25(OH)D levels was 0.88 (0.81, 0.97) in dose–response analysis. Evidence was lacking of heterogeneity among studies that measured blood 25(OH) D levels and those that assessed dietary vitamin D status. Studies are needed to determine whether the association of vitamin D with hypertension represents a causal association and also to determine whether vitamin D therapy may be beneficial in the prevention or the treatment of hypertension.

Keywords

Vitamin D Blood pressure Hypertension Meta-analysis 

Notes

Conflict of interest

None.

Supplementary material

10654_2013_9790_MOESM1_ESM.doc (56 kb)
Supplementary material 1 (DOC 56 kb)

References

  1. 1.
    DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clini Nutr. 2004;80(6 Suppl):1689S–96S.Google Scholar
  2. 2.
    Wallis DE, Penckofer S, Sizemore GW. The “sunshine deficit” and cardiovascular disease. Circulation. 2008;118(14):1476–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Khan H, Kunutsor S, Franco OH, Chowdhury R. Vitamin D. Type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc Nutr Soc. 2013;72(1):89–97. doi: 10.1017/S0029665112002765.Google Scholar
  4. 4.
    Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168(11):1174–80. doi: 10.1001/archinte.168.11.1174.PubMedCrossRefGoogle Scholar
  5. 5.
    Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004–13.PubMedCrossRefGoogle Scholar
  6. 6.
    Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167(11):1159–65. doi: 10.1001/archinte.167.11.1159.PubMedCrossRefGoogle Scholar
  8. 8.
    Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007;20(7):713–9. doi: 10.1016/j.amjhyper.2007.01.017.PubMedCrossRefGoogle Scholar
  9. 9.
    Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 2008;87(1):136–41.PubMedGoogle Scholar
  10. 10.
    Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52(5):828–32. doi: 10.1161/HYPERTENSIONAHA.108.117630.PubMedCrossRefGoogle Scholar
  11. 11.
    Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49(5):1063–9. doi: 10.1161/HYPERTENSIONAHA.107.087288.PubMedCrossRefGoogle Scholar
  12. 12.
    Griffin FC, Gadegbeku CA, Sowers MR. Vitamin D and subsequent systolic hypertension among women. Am J Hypertens. 2011;24(3):316–21. doi: 10.1038/ajh.2010.226.PubMedCrossRefGoogle Scholar
  13. 13.
    Margolis KL, Martin LW, Ray RM, Kerby TJ, Allison MA, Curb JD, et al. A prospective study of serum 25-hydroxyvitamin D levels, blood pressure, and incident hypertension in postmenopausal women. Am J Epidemiol. 2012;175(1):22–32. doi: 10.1093/aje/kwr274.PubMedCrossRefGoogle Scholar
  14. 14.
    Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307–14. doi: 10.1059/0003-4819-152-5-201003020-00009.PubMedGoogle Scholar
  15. 15.
    Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens. 2011;29(4):636–45. doi: 10.1097/HJH.0b013e32834320f9.PubMedCrossRefGoogle Scholar
  16. 16.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.PubMedCrossRefGoogle Scholar
  17. 17.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of Observational Studies in Epidemiology. J Am Med Assoc. 2000;283(15):2008–12. doi: 10.1001/jama.283.15.2008.CrossRefGoogle Scholar
  18. 18.
    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed 20 Aug 2012.
  19. 19.
    Chêne G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol. 1996;144(6):610–21.PubMedCrossRefGoogle Scholar
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRefGoogle Scholar
  21. 21.
    Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135(11):1301–9.PubMedGoogle Scholar
  22. 22.
    Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J. 2006;6:40–57.Google Scholar
  23. 23.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi: 10.1136/bmj.327.7414.557.PubMedCrossRefGoogle Scholar
  24. 24.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. doi: 10.1002/sim.1186.PubMedCrossRefGoogle Scholar
  25. 25.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRefGoogle Scholar
  26. 26.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCrossRefGoogle Scholar
  27. 27.
    Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ, Curhan GC. Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension. 2005;46(4):676–82. doi: 10.1161/01.HYP.0000182662.82666.37.PubMedCrossRefGoogle Scholar
  28. 28.
    Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963–8. doi: 10.1016/j.amjcard.2010.05.027.PubMedCrossRefGoogle Scholar
  29. 29.
    Jorde R, Figenschau Y, Emaus N, Hutchinson M, Grimnes G. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension. 2010;55(3):792–8. doi: 10.1161/HYPERTENSIONAHA.109.143990.PubMedCrossRefGoogle Scholar
  30. 30.
    Wang L, Manson JE, Buring JE, Lee I-M, Sesso HD. Dietary intake of diary products, calcium, and vitamin D and risk of hypertension in middle-aged and older women. Hypertension. 2008;51:1073–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Sterne J, Becker B, Egger M. The funnel plot. In: Rothstein H, Sutton A, Borenstein M, editors. Publication bias in meta-analysis. prevention, assessment and adjustments. Chichester, United Kingdom: Wiley; 2005.Google Scholar
  32. 32.
    Lee JH, O’Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52(24):1949–56. doi: 10.1016/j.jacc.2008.08.050.PubMedCrossRefGoogle Scholar
  33. 33.
    Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79(5):820–5.PubMedGoogle Scholar
  34. 34.
    Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007;71(2):134–9. doi: 10.1038/sj.ki.5002002.PubMedCrossRefGoogle Scholar
  35. 35.
    Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med: J Brit Diabet Assoc. 2008;25(3):320–5.CrossRefGoogle Scholar
  36. 36.
    Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11. doi: 10.1161/CIRCULATIONAHA.107.706127.PubMedCrossRefGoogle Scholar
  37. 37.
    Dawson-Hughes B. What is the Optimal Dietary Intake of Vitamin D for Reducing Fracture Risk? Calcif Tissue Int. 2012;[Epub ahead of print]. Google Scholar
  38. 38.
    Norman PE, Vitamin Powell JT. Vitamin D shedding light on the development of disease in peripheral arteries. Arterioscler Thromb Vasc Biol. 2005;25(1):39–46. doi: 10.1161/01.ATV.0000148450.56697.4a.PubMedGoogle Scholar
  39. 39.
    Feskanich D, Willett WC, Colditz GA. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am J Clin Nutr. 2003;77(2):504–11.PubMedGoogle Scholar
  40. 40.
    Willett W. Nutritional Epidemiology. 2nd Edition ed. New York: Oxford University; 1998.Google Scholar
  41. 41.
    Sonderman JS, Munro HM, Blot WJ, Signorello LB. Reproducibility of serum 25-hydroxyvitamin d and vitamin D-binding protein levels over time in a prospective cohort study of black and white adults. Am J Epidemiol. 2012;176(7):615–21. doi: 10.1093/aje/kws141.PubMedCrossRefGoogle Scholar
  42. 42.
    Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev: Publ Am Assoc Cancer Res Cosponsor Am Soc Prevent Oncol. 2010;19(4):927–31. doi: 10.1158/1055-9965.EPI-09-1121.CrossRefGoogle Scholar
  43. 43.
    Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabet Care. 2004;27(12):2813–8.CrossRefGoogle Scholar
  44. 44.
    Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. doi: 10.1136/bmj.c221.PubMedCrossRefGoogle Scholar
  45. 45.
    Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. The. J Clin Endocrinol Metab. 2011;96(7):1931–42. doi: 10.1210/jc.2011-0398.PubMedCrossRefGoogle Scholar
  46. 46.
    Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009;27(10):1948–54. doi: 10.1097/HJH.0b013e32832f075b.PubMedCrossRefGoogle Scholar
  47. 47.
    Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159–71. doi: 10.1016/j.cct.2011.09.009.PubMedCrossRefGoogle Scholar
  48. 48.
    Davey Smith G, Ebrahim S. Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22.CrossRefGoogle Scholar
  49. 49.
    Dastani Z, Li R, Richards B. Genetic regulation of vitamin D levels. Calcif Tissue Int. 2012;. doi: 10.1007/s00223-012-9660-z.PubMedGoogle Scholar
  50. 50.
    Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376(9736):180–8. doi: 10.1016/S0140-6736(10)60588-0.PubMedCrossRefGoogle Scholar
  51. 51.
    Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-wide association study of circulating vitamin D levels. Hum Molecul Genet. 2010;19(13):2739–45. doi: 10.1093/hmg/ddq155.CrossRefGoogle Scholar
  52. 52.
    Berry DJ, Vimaleswaran KS, Whittaker JC, Hingorani AD, Hypponen E. Evaluation of genetic markers as instruments for mendelian randomization studies on vitamin D. PLoS One. 2012;7(5):e37465.PubMedCrossRefGoogle Scholar
  53. 53.
    Lind L, Wengle B, Ljunghall S. Blood pressure is lowered by vitamin D (Alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. Acta Med Scand. 1987;222:423–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Lind L, Lithell H, Skarfors E, Wide L, Ljunghall S. Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. Acta Med Scand. 1988;223(3):211–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Lind L, Wengle B, Wide L, Sorensen OH, Ljunghall S. Hypertension in primary hyperparathyroidism--reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol). A double-blind, placebo-controlled study. Am J Hypertens. 1988;1(4 Pt 1):397–402.PubMedCrossRefGoogle Scholar
  56. 56.
    Zoccali C, Mallamaci F, Delfino D, Ciccarelli M, Parlongo S, Iellamo D, et al. Double-blind randomized, crossover trial of calcium supplementation in essential hypertension. J Hypertens. 1988;6(6):451–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Lind L, Wengle B, Wide L, Ljunghall S. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertens. 1989;2(1):20–5.PubMedGoogle Scholar
  58. 58.
    Orwoll ES, Oviatt S. Relationship of mineral metabolism and long-term calcium and cholecalciferol supplementation to blood pressure in normotensive men. Am J Clin Nutr. 1990;52(4):717–21.PubMedGoogle Scholar
  59. 59.
    Myrup B, Jensen GF, McNair P. Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment. Arch Intern Med. 1992;152(11):2265–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Pan WH, Wang CY, Li LA, Kao LS, Yeh SH. No significant effect of calcium and vitamin D supplementation on blood pressure and calcium metabolism in elderly Chinese. Chin J Physiol. 1993;36(2):85–94.PubMedGoogle Scholar
  61. 61.
    Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Europ J Clin Nutr. 1995;49(9):640–6.Google Scholar
  62. 62.
    Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet. 1998;352(9129):709–10.PubMedCrossRefGoogle Scholar
  63. 63.
    Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86(4):1633–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754–9.PubMedGoogle Scholar
  65. 65.
    Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85(1):54–9.PubMedGoogle Scholar
  66. 66.
    Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Medicine: J Brit Diabet Assoc. 2009;26(1):19–27. doi: 10.1111/j.1464-5491.2008.02636.x.CrossRefGoogle Scholar
  67. 67.
    Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR, et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women’s Health Initiative Randomized Trial. Hypertension. 2008;52(5):847–55. doi: 10.1161/HYPERTENSIONAHA.108.114991.PubMedCrossRefGoogle Scholar
  68. 68.
    Daly RM, Nowson CA. Long-term effect of calcium-vitamin D(3) fortified milk on blood pressure and serum lipid concentrations in healthy older men. Europ J Clin Nutr. 2009;63(8):993–1000. doi: 10.1038/ejcn.2008.79.CrossRefGoogle Scholar
  69. 69.
    Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med. 2010;267(5):462–72.PubMedCrossRefGoogle Scholar
  70. 70.
    Bolland MJ, Bacon CJ, Horne AM, Mason BH, Ames RW, Wang TK, et al. Vitamin D insufficiency and health outcomes over 5 y in older women. Am J Clin Nutr. 2010;91(1):82–9. doi: 10.3945/ajcn.2009.28424.PubMedCrossRefGoogle Scholar
  71. 71.
    Judd SE, Raiser SN, Kumari M, Tangpricha V. 1,25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: a pilot feasibility study. J Steroid Biochem Mol Biol. 2010;121(1–2):445–7. doi: 10.1016/j.jsbmb.2010.04.013.PubMedCrossRefGoogle Scholar
  72. 72.
    de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543–51. doi: 10.1016/S0140-6736(10)61032-X.PubMedCrossRefGoogle Scholar
  73. 73.
    Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2010;53(10):2112–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Shab-Bidar S, Neyestani TR, Djazayery A, Eshraghian MR, Houshiarrad A, Gharavi A, et al. Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial. BMC Med. 2011;9:125. doi: 10.1186/1741-7015-9-125.PubMedCrossRefGoogle Scholar
  75. 75.
    Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens. 2012;25(11):1215–22. doi: 10.1038/ajh.2012.111.PubMedCrossRefGoogle Scholar
  76. 76.
    Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2012;59(1):67–74. doi: 10.1053/j.ajkd.2011.09.014.PubMedCrossRefGoogle Scholar
  77. 77.
    Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674–84. doi: 10.1001/jama.2012.120.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Setor Kwadzo Kunutsor
    • 1
    • 2
    Email author
  • Tanefa Antoinette Apekey
    • 2
  • Marinka Steur
    • 1
  1. 1.Department of Public Health and Primary CareUniversity of CambridgeCambridgeUK
  2. 2.Institute of Health Sciences, Faculty of Medicine and HealthUniversity of LeedsLeedsUK

Personalised recommendations